Evidence map›Paper›PMID 30846752›Full record

ArticleScientific reports2019

Responsive Cells for rhEGF bioassay Obtained through Screening of a CRISPR/Cas9 Library.

Xi Qin, Wenrong Yao, Xinchang Shi, Lan Liu, Fang Huang, Youxue Ding, Yong Zhou, Lei Yu, Chuncui Jia, Shanhu Li and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Scientific reports, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Xi QinDepartment of Recombinant Products, National Institutes for Food and Drug Control, Beijing, 100050, China.
Wenrong YaoDepartment of Recombinant Products, National Institutes for Food and Drug Control, Beijing, 100050, China.
Xinchang ShiDepartment of Recombinant Products, National Institutes for Food and Drug Control, Beijing, 100050, China.
Lan LiuDepartment of Recombinant Products, National Institutes for Food and Drug Control, Beijing, 100050, China.
Fang HuangDepartment of Cell Engineering, Beijing Institute of Biotechnology, Beijing, 100850, China.
Youxue DingDepartment of Recombinant Products, National Institutes for Food and Drug Control, Beijing, 100050, China.
Yong ZhouDepartment of Recombinant Products, National Institutes for Food and Drug Control, Beijing, 100050, China.
Lei YuDepartment of Recombinant Products, National Institutes for Food and Drug Control, Beijing, 100050, China.
Chuncui JiaDepartment of Recombinant Products, National Institutes for Food and Drug Control, Beijing, 100050, China.
Shanhu LiDepartment of Cell Engineering, Beijing Institute of Biotechnology, Beijing, 100850, China. lishanhu6@163.com.
Chunming RaoDepartment of Recombinant Products, National Institutes for Food and Drug Control, Beijing, 100050, China. raocm@nifdc.org.cn.
Junzhi WangDepartment of Recombinant Products, National Institutes for Food and Drug Control, Beijing, 100050, China. wangjz@nifdc.org.cn.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Bioassay of recombinant protein products is important tests to ensure protein effectiveness. Some recombinant protein products have no cells used in their bioassay but instead use animal models, while others have no suitable method. Here, we developed a method to obtain responsive cells used in bioassay of proteins. After screening of a CRISPR/Cas9 library, we obtained a responsive cell line that grew faster in the presence of rhEGF (recombinant human epidermal growth factor) than that of control cells. We used this cell line for bioassay of rhEGF. This cell line, compared with the control cells, had a 2 day shorter operation time and had lower interference. The responsive cell line is more suitable for use in bioassay of rhEGF.

Indexed as

CRISPR-Cas SystemsAnimalsBiological AssayEpidermal Growth FactorGene Knockout TechniquesHumansLoss of Function MutationMiceNIH 3T3 CellsReproducibility of ResultsEpidermal Growth Factor

Identifiers

PMID30846752
PMCPMC6405917

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.